Modern Ideas of the Pathogenetic Mechanism of Allergodermatoses and New Possibilities of Complex Therapy
Keywords:
allergodermatoses, atopic dermatitis, allergic contact dermatitis, external therapy, glucocorticosteroidsAbstract
Diseases of the skin and subcutaneous tissue, including allergodermatoses, are widespread among the population of developed countries. The prevalence of contact dermatitis among frequently occurring skin nosologies reaches 53%, atopic dermatitis - 19%, eczema - 17% [1]. One of the most severe dermatoses is atopic dermatitis (AtD). The incidence of AtD in recent years tends to increase. In this regard, the problem of studying new data on the pathogenesis of the disease and searching for pathogenetically justified methods of therapy of allergic dermatoses remains relevant.
References
Glukhova E.A., Mukhortykh V.A., Tamrazova O.B., Taganov A.V., Revyakina V.A. Predictors of severe atopic dermatitis. Nutrition issues. 2022;91(1):76–85. 2.Tamrazova O.B., Taganov A.V., Revyakina V.A. Predictors of severe course of atopic dermatitis. Voprosy Pitaniia. 2022;91(1):76–85
Siegfried E.C., Jaworski J.C., Kaiser J.D., Hebert A.A. Systematic review of published trials: long-term safety of topical corticosteroids and topical calcineurin inhibitors in pediatric patients with atopic dermatitis. BMC Pediatr. 2016;(16):75.
Mancini A.J., Kaulback K., Chamlin S.L. The socioeconomic impact of atopic dermatitis in the United States: a systematic review. Pediatr Dermatol. 2008;25(1):1–6.
Kim J.P., Chao L.X., Simpson E.L., Silverberg J.I. Persistence of atopic dermatitis (AD): a systematic review and meta-analysis. J Am Acad Dermatol. 2016;75(4):681–687.
Boguniewicz M., Fonacier L., Guttman-Yassky E., Ong P.Y., Silverberg J., Farrar J.R. Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape. Ann Allergy Asthma Immunol. 2018;120(1):10–22.e2.
Sayaseng K.Y., Vernon P. Pathophysiology and management of mild to moderate pediatric atopic dermatitis. J Pediatr Health Care. 2018;32(2):S2–S12.
Pustišek N., Živković M.V., Šitum M. Quality of life in fami lies with children with atopic dermatitis. Pediatr Dermatol. 2016;33(1):28–32
Kuo I.H., Yoshida T., De Benedetto A., Beck L.A. The cutaneous innate immune response in patients with atopic dermatitis. J Allergy Clin Immunol. 2013;131(2):266–278..
Boguniewicz M., Leung D.Y.M. Atopic dermatitis: a disease of altered skin barrier and immune dysregulation. Immunol Rev. 2011;242(1):233–246.
Irvine A.D., Mclean W.H.I., Leung D.Y.M. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med. 2011;365(14):1315–1327.
Wollenberg A., Barbarot S., Bieber T., Christen-Zaech S., Deleuran M., Fink-Wagner A. et al. Global Allergy and Asthma European Network (GA2LEN) and the European Union of Medical Specialists (UEMS) Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: Part I. J Eur Acad Dermatol Venereol. 2018;32(5):657–682.
Eichenfield L.F., Tom W.L., Berger T.G., Krol A., Paller A.S., Schwarzenberg K. et al. Guidelines of care for the management of atopic dermatitis: Section 2. Management and treatment of atopic dermatitis with topical therapies. J Am Acad Dermatol. 2014;71(1):116–132.
Kapur S., Watson W., Carr S. Atopic dermatitis. Allergy Asthma Clin Immunol. 2018;14(2):52.
Rathi S.K., D’Souza P. Rational and ethical use of topical corticosteroids based on safety and efficacy. Indian J Dermatol. 2012;57(4):251–259.
Hughes J., Rustin M. Corticosteroids. Clin Dermatol. 1997;15(5):715–721. https://doi.org/10.1016/s0738-081x(97)00020-5. 16. Charman C.R., Morris A.D., Williams H.C. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol. 2000;142(5):931–936.
